|Bid||752,000.00 x 0|
|Ask||753,000.00 x 0|
|Day's Range||750,000.00 - 764,000.00|
|52 Week Range||352,000.00 - 883,000.00|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 19, 2021 - Apr 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||499,500.00|
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the global market.
Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excellence in overcoming various challenges and global uncertainties amid the COVID-19 pandemic throughout the year.
Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference. John Rim, newly appointed President and CEO, unveiled a multidimensional business plan for the company to further expand as a major player in the biopharmaceutical industry, bolstering its rapidly expanding CDMO business with a greater global footprint, continued advancements in its biosimilars subsidiary, and ultimately new drug development.